Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1551-1556

  Hobday, Timothy J ^a   Qin, Rui ^a   Reidy Lagunes, Diane ^b   Moore, Malcolm J ^d   Strosberg, Jonathan ^e   Kaubisch, Andreas ^c   Shah, Manisha ^f   Kindler, Hedy Lee ^g   Lenz, Heinz Josef ^h   Chen, Helen ⁱ   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ADULT; ANEMIA; ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84933502992     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.2082     Document Type: Article

References (13)

1. Halfdanarson TR, Rabe KG, Rubin J, et al: Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727-1733, 2008
2. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-flourouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992
3. Kulke MH, Hornick JL, Krauenhoffer C, et al: 06-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15:338-345, 2009
4. Strosberg JR, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:168-175, 2011
5. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
6. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-503, 2011
7. Stephen S, Datta K, Wang E, et al: Effect of rapamycin alone and in combination with antiangiogenesis therapy in orthotopic model of human pancreatic cancer. Clin Cancer Res 10:6993-7000, 2004
8. Merchan JR, Liu G, Fitch T, et al: Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol 25:243s, 2007 (suppl; abstr 5034)
9. Hobday TJ, Mahoney M, Erlichman C, et al: Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 23:198s, 2005 (suppl; abstr 4083)
10. Duran I, Kortmansky J, Singh D, et al: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154, 2006
11. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
12. Yao JC, Phan A, Hoff PM, et al: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha 2-b. J Clin Oncol 26:1316-1323, 2008
13. Rini BI, Bellmunt J, Clancy J, et al: Randomized phase III trial of temsirolimus and bevacizumab versus interferon also and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32:752-759, 2014